Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy
Progressive Supranuclear Palsy (PSP) is a relentlessly progressive neurodegenerative disorder, clinically characterized by parkinsonism with prominent axial involvement and postural instability, bulbar symptoms, supranuclear ophthalmoplegia, and executive dysfunction. Abnormal neuronal and glial tau aggregations affecting the basal ganglia and selective brainstem structures result in dysfunction of the five frontosubcortical circuits and brainstem functions. There is no effective treatment for PSP. One of the key feature in the aggregation of tau is its phosphorylation by kinases such as glycogen synthase kinase 3b (GSK3b). Recent reports have shown that valproic acid was able to inhibit the activity of GSK3b and could exert a neuroprotective effect through this inhibition. The investigators thus decided to conduct this controlled study to assess the putative neuroprotective effects in patients with PSP.
PSPRS score (specific score for PSP)
Progressive Supranuclear Palsy
Study Arms / Comparison Groups
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - Patients with possible or probable PSP - from 45 to 75 year of age
45 Years - 75 Years
Accepts Healthy Volunteers
Pascal Derkinderen, ,
Nantes University Hospital
Pascal Derkinderen, Principal Investigator, Nantes University Hospital